PXD030881

PXD030881 is an original dataset announced via ProteomeXchange.

Title	TMT 10-plex based quantitative proteomic analysis of drug resistant breast cancer cell lines
Description	Breast cancer accounts for roughly 30% of all cancers in women worldwide, has a 15% death rate, and incidence rates are increasing at a rate of about 0.5% per year. Breast cancer comprises a heterogeneous group of tumor subtypes, whether defined by the histopathology of the primary tumor, the expression pattern of hormone receptors (estrogen and/or progesterone receptors; ER/PR) and epidermal growth factor receptor 2 (HER2), genetic alterations of transcriptomic traits. These patient-to-patient differences (as known as �쁦ntertumoral heterogeneity��, largely affect patient prognosis and treatment options. Alongside intertumoral heterogeneity, many studies reported that breast cancers heterogeneous consisting of many different cells or subclones of which different gene expression profiles within a patient�셲 primary tumor and individual metastases. These differences within the tumor are referred to as intratumor heterogeneity, which is caused by a combination of extrinsic factors from the tumor microenvironment and intrinsic parameters including genetic, epigenetic and transcriptomic traits, ability of proliferation, migration and invasion, cell plasticity, and the extent of stemness. These heterogeneities endow tumors with multiple capabilities and biological characteristics, making them more prone to metastasis, recurrence, and drug resistance. To overcome these facing challenges, understanding the proteome mechanisms behind transcriptome profiling from the aspect of treatment can help to improve resistance to cancer therapy. Recent proteomics technologies based on mass spectrometry enable an unbiased investigation of drug-induced changes in protein abundance and post-translational modifications. Several studies on resistance to chemotherapy have recently published data on mass spectrometry-based chemotherapeutic proteome profiling, which has the potential to discover molecular subtypes and related pathway features that may have been missed in prior transcriptome analyses. Nevertheless, few proteomics studies to date explore three types of drug-specific resistance of breast cancer signatures. In this study, we employed tandem mass tag (TMT) based proteomics technology to process the acquired mass spectrometry data to test the hypothesis that the chemotherapy in breast cancer cells may have distinct protein profiles that may result in their drug properties and new clinical implications. By unraveling the protein signatures across tamoxifen, doxorubicin, and paclitaxel and their relationship between drug-resistant cell lines and normal breast cancer cells, our study advances the understanding of drug-specific resistance and provides potential diagnostic and prognostic markers, as well as testable targets of therapy specific to breast cancer resistant cells.
HostingRepository	PRIDE
AnnounceDate	2024-10-07
AnnouncementXML	Submission_2024-10-07_11:01:34.082.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Dohyun Han
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2022-01-11 01:15:50	ID requested
⏵ 1	2024-10-07 11:01:35	announced

10.3390/molecules27061762;

Cha HK, Cheon S, Kim H, Lee KM, Ryu HS, Han D, Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics Analysis. Molecules, 27(6):(2022) [pubmed]

submitter keyword: Human, TMT, Breast Cancer, Drug Resistance

Dohyun Han
contact affiliation	Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital
contact email	hdh03@snu.ac.kr
lab head
Dohyun Han
contact affiliation	Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital
contact email	hdh03@snu.ac.kr
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/04/PXD030881

PRIDE project URI

• PRIDE
  1. PXD030881
     1. Label: PRIDE project
     2. Name: TMT 10-plex based quantitative proteomic analysis of drug resistant breast cancer cell lines